Cite
Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice.
MLA
Quarcoo, D., et al. “Resiquimod, a New Immune Response Modifier from the Family of Imidazoquinolinamines, Inhibits Allergen-Induced Th2 Responses, Airway Inflammation and Airway Hyper-Reactivity in Mice.” Clinical & Experimental Allergy, vol. 34, no. 8, Aug. 2004, pp. 1314–20. EBSCOhost, https://doi.org/10.1111/j.1365-2222.2004.02023.x.
APA
Quarcoo, D., Weixler, S., Joachim, R. A., Stock, P., Kallinich, T., Ahrens, B., & Hamelmann, E. (2004). Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice. Clinical & Experimental Allergy, 34(8), 1314–1320. https://doi.org/10.1111/j.1365-2222.2004.02023.x
Chicago
Quarcoo, D., S. Weixler, R. A. Joachim, P. Stock, T. Kallinich, B. Ahrens, and E. Hamelmann. 2004. “Resiquimod, a New Immune Response Modifier from the Family of Imidazoquinolinamines, Inhibits Allergen-Induced Th2 Responses, Airway Inflammation and Airway Hyper-Reactivity in Mice.” Clinical & Experimental Allergy 34 (8): 1314–20. doi:10.1111/j.1365-2222.2004.02023.x.